Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Article
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
[powerpress]
